Acción 603351 NANJING WELL PHARMACEUTICAL GROUP CO.,LTD.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Nanjing Well Pharmaceutical Group Co.,Ltd.

Acciones

603351

CNE100003JD4

Precio de cierre Shanghai S.E.
Otros sitios de cotización
 00:00:00 12/06/2024 		Varia. Cinco días. Varia. 1 de enero.
21,63 CNY +1,64 % Gráfico intradía de Nanjing Well Pharmaceutical Group Co.,Ltd. +1,74 % -17,97 %
25/04 Nanjing Well Pharmaceutical Group Co.,Ltd. Resultados del primer trimestre finalizado el 31 de marzo de 2024 CI
2023 Nanjing Well Pharmaceutical Group Co.,Ltd. informa de los resultados de los nueve meses finalizados el 30 de septiembre de 2023 CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!
Inscripción 100% Gratuita
Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
Nanjing Well Pharmaceutical Group Co.,Ltd. completed the acquisition of13% stake in Nanjing Xingwei Biotechnology Co., Ltd. from Wu Renrong, Gao Zhengsong, Chen Xinguo, Tang Qunsong, Shen Jiusi, Wu Rongwen, Hong Shilin, Zou Jianguo, Wang Fuqiu and Zhou Chong.
Nanjing Well Pharmaceutical Group Co.,Ltd. signed an agreement to acquire 13% stake in Nanjing Xingwei Biotechnology Co., Ltd. from Wu Renrong, Gao Zhengsong, Chen Xinguo, Tang Qunsong, Shen Jiusi, Wu Rongwen, Hong Shilin, Zou Jianguo, Wang Fuqiu and Zhou Chong for CNY0.
Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
Certain A Shares of Nanjing Well Pharmaceutical Co., Ltd. are subject to a Lock-Up Agreement Ending on 30-JAN-2022.
Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021
Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021
Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021
Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020
Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020
Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2020
Nanjing Well Pharmaceutical Group Co.,Ltd.(XSSC:603351) dropped from S&P Global BMI Index
Nanjing Well Pharmaceutical Co., Ltd. Announces Cash Dividend for the Year 2019, Payable on May 27, 2020
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción 603351
  4. Noticias Nanjing Well Pharmaceutical Group Co.,Ltd.
  5. Otros idiomas